Title: PREVENTING AND TREATING SEPSIS

Abstract: Provided are polypeptides comprising a variant activated protein C comprising one or more amino acid substitutions selected from the group consisting of K146R, D172N, C212R, K146G, R147G, R177G and combinations thereof. Also provided are nucleic acids encoding the polypeptides, and cells, compositions and kits containing the polypeptides and nucleic acids. Also provided are methods of treating sepsis in a subject comprising administering to the subject one or more of the provided polypeptides or nucleic acids. Methods of screening for polypeptides with enhanced activated protein C and for an agent for treatment of sepsis are provided. Finally, provided is a method of treating sepsis in a subject comprising administering to the subject a pharmaceutical composition comprising one or more RGD-containing peptides.
as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(Hi))

Published:
— without international search report and to be republished upon receipt of that report (Rule 48.2(g))
Preventing and Treating Sepsis

CROSS-REFERENCE TO RELATED APPLICATION
This application claims priority to U.S. Provisional Application No. 61/10,867, filed November 3, 2008, which is incorporated by reference herein in its entirety.

STATEMENT REGARDING FEDERALLY FUNDED RESEARCH
This invention was made with government support under Grant Nos. HL087088, HL18208, HL68571, GM065085 and GM066194 awarded by the National Institutes of Health. The government has certain rights in the invention.

BACKGROUND
Migration of leukocytes to infection sites is vital for pathogen clearance and, thus, for host survival. Interaction of cell surface integrins with their counterpart ligands, which are expressed on the endothelial surface, results in the localization and adherence of circulating neutrophils to endothelial cells. This is followed by neutrophil activation and directed migration to sites of infection through the extracellular matrix. An important function of integrins is to concentrate neutrophils at the infection site, ensuring that their immune products and activities remain at this site, while minimizing unnecessary injury to uninfected tissues. Sustained or dysregulated integrin activation, resulting in abnormal neutrophil trafficking, as well as direct damage to the vasculature and the underlying tissue, is known to contribute to sepsis. Recombinant human activated protein C (rhAPC) is the only FDA-approved drug for treating severe sepsis. APC is a vitamin-K dependent serine protease that is derived from protein C (PC) and is well known for its anticoagulant functions.

SUMMARY
Provided are polypeptides comprising a variant activated protein C. Specifically, provided are polypeptides comprising an activated protein C (APC) polypeptide comprising one or more amino acid substitutions selected from the group consisting of K146R, D172N, C212R, K146G, R147G, R177G and combinations thereof. Also provided are nucleic acids encoding the polypeptides, and cells, compositions and kits containing the polypeptides and nucleic acids.
Provided are methods of treating sepsis in a subject comprising administering to the subject a variant activated protein C. The variant includes one or more amino acid substitutions selected from the group consisting of K146R, D172N, C212R, K146G, R147G, R177G and combinations thereof.

Methods of screening for polypeptides with enhanced activated protein C activity are provided. For example, the methods include contacting a polypeptide to be tested with a cell expressing one or both of β1 integrin and β3 integrin, wherein the polypeptide to be tested comprises activated protein C or a fragment thereof comprising one or more amino acid substitutions, and determining whether the polypeptide to be tested binds to the β1 integrin or β3 integrin better than a control activated protein C or fragment thereof. Binding better than the control indicates the polypeptide to be tested has enhanced activated protein C activity.

Also provided are methods of screening for an agent for the treatment of sepsis. The method includes contacting the agent to be screened with a cell expressing one or both of β1 integrin and β3 integrin, contacting an activated protein C or fragment thereof with the cell, and determining whether the agent competes with APC for binding to the β1 integrin or β3 integrin. If the agent competes with APC for binding, this indicates the agent is suitable for the treatment of sepsis.

Further provided is a method of treating sepsis in a subject comprising administering to the subject a pharmaceutical composition comprising one or more RGD-containing peptides.

**DESCRIPTION OF DRAWINGS**

Figures 1A-1E show recombinant human activated protein C (rhAPC) inhibits neutrophil migration. Figure 1A shows live cell images of migration of human neutrophils on fibronectin (FN)-coated cover glasses in the presence of N-formyl-Met-Leu-Phe (fMLP) ± rhAPC. Cells were tracked over a 30 min period, and each line represents one cell. Experiments were repeated on neutrophil preparations from three independent donors. Figure 1B shows directional migration of neutrophils, as measured by the under-agarose migration assay. The number of control or rhAPC-treated neutrophils migrating to fMLP (1 and 2) or to PBS (3) was counted. Representative data from three independent experiments are shown. Figure 1C shows center-zeroed tracks of control or rhAPC-treated neutrophils migrating towards
microtips containing fMLP. The scale of each graph is in µm. The speed (S, µm sec\(^{-1}\)), migratory index (MI), and X\(^{D}\) (mean direction in which the population is moving in degrees) are shown (mean ± SEM). Figure 1D shows migration of human neutrophils on FN coated-cover glasses in the presence of IL-8 ± rhAPC. Figure 1E shows cytosolic Ca\(^{2+}\) levels in stirred Fluo-4-labeled neutrophils continuously measured in a fluorometer. Control (PBS) or rhAPC treated neutrophils in Ca\(^{2+}\) containing buffer were sequentially stimulated with 10 nM fMLP and 40 µM digitonin. The data are representative of at least three independent experiments.

Figures 2A-2G show direct binding of rhAPC to neutrophil integrins. Figure 2A shows binding of control or 10 nM fMLP-treated neutrophils to immobilized FN in the presence of rhAPC (10 µg/ml) or Gla-less APC (10 µg/ml), or an equivalent amount of PBS. Figure 2B shows an alignment of RGD sequences (gray) in human fibronectin (FN) (SEQ ID NO:40) and human protein C (SEQ ID NO:41). Figure 2C shows a histogram of binding of rhAPC to human neutrophils assayed using chromogenic substrate S-2366 in the presence of 1 mM MnCl\(_2\) ± cyclic RGD peptide (20 µg/ml), β1 blocking Ab, β3 blocking Ab, or β2 blocking Ab (10 µg/ml each). *P < 0.05 vs. MnCl\(_2\) treated cells. Figure 2D shows histograms of induction of ligand-induced binding site (LIBS) epitopes by rhAPC. Control (PBS) or rhAPC-treated neutrophils were incubated with the indicated concentrations of MgCl\(_2\) and CaCl\(_2\).

The LIBS of β1 and β3 integrins were detected by B44 and D3 mAb, respectively. *P < 0.05 vs. PBS treated cells. Figure 2E shows histograms of solid phase binding of immobilized αβ1, αβ3, and αβ3 to FN or rhAPC. Figure 2F shows a histogram of solid phase binding of immobilized αβ1, αβ1, and αβ3 to wild type or mutant rhAPC (RGE-APC). Figure 2G shows migration of human neutrophils on FN coated-cover glasses in the presence of fMLP ± rhPC, rhAPC, or RGE-APC. Experiments were repeated on neutrophil preparations from three independent donors. In Figures 2A, 2C, 2D, 2E, and 2F, results are expressed as mean ± SEM of three independent experiments.

Figures 3A-3F show simultaneous binding of rhAPC to neutrophil integrins and EPCR. Figure 3A shows EPCR RT-PCR on human neutrophils. Reverse transcribed cDNAs from human heart and lung served as positive controls (upper panel). FACS analysis of cell surface EPCR (lower panel). fMLP-treated cells were exposed to fMLP for 30min prior to fixation. Figure 3B shows histograms of binding
of 10 nM fMLP-treated neutrophils to immobilized FN in the presence of rhAPC (10 µg/ml) ± EPCR mAb (50 or 100 µg/ml). Figure 3C shows a hypothetical model for rhAPC binding. Cells expressing hEPCR-mCFP and βl-mYFP exhibit FRET only when these two molecules are brought into close proximity (100 Å) after rhAPC binding. Figure 3D shows Western blots of whole cell lysates of HEK293 cells transiently transfected with hEPCR-mCFP and βl-mYFP K562 and subjected to SDS-PAGE. Figure 3E shows fluorescence images of transiently transfected HEK293 cells with hEPCR-mCFP and βl-mYFP demonstrating membrane localization of CFP and YFP signals. Figure 3F shows HEK293 cells transfected with hEPCR-mCFP and βl-mYFP in delta T dish. FRET was measured by sensitized emission method and analyzed by AutoQuant software.

Figures 4A-4C show the RGD sequence of rhAPC is critical for inhibition of neutrophil migration in vivo. Figure 4A shows a histogram of neutrophil counts in BALF from LPS treated mice. Mice were given rhAPC or RGE-APC (10 µg/mouse) or PBS 2 hours after LPS treatment. *P < 0.05 between mice treated with rhAPC and PBS; n = 7 per group. Figure 4B shows survival curves for mice after CLP. 200 µg of the RGD peptide or PBS was given 12 hours before and after CLP via i.v. injection (n=20 per group). Figure 4C shows survival curves for mice challenged with an LD90 of LPS. 200 µg of the RGD peptide or PBS was given via i.v. injection before receiving 40-39 mg/kg of LPS (i.p.) (n=10 per group). The statistical significance of mortality was determined by the Kaplan-Meyer log-rank test.

Figure 5 shows two-dimensional (2D) and three-dimensional (3D) structures of APC.

Figure 6 is a schematic drawing of the expression of the protein of interest as a fusion to agglutinin in a yeast display system.

Figures 7A and 7B show cycles of panning of a yeast library on HEK293 cells. Figure 7A shows images of increasing cycles of panning of a yeast library on HEK293 cells. Figure 7B shows a histogram of recovery percentage for increasing cycles of panning of a yeast library on HEK293 cells.

Figure 8 shows the location of the C212R mutation.

Figures 9A shows the locations of KR146/147GG and R177G. Figure 9B shows a histogram of binding of yeast that express mutant APCs on HEK293 cells.
DETAILED DESCRIPTION

During inflammation, tissue injury results from excessive infiltration and sequestration of activated leukocytes. Recombinant human activated protein C (rhAPC) has been shown to protect patients with severe sepsis, although this protective effect remains unclear. As described herein, rhAPC was demonstrated to directly bind to β1 and β3 integrins and to inhibit neutrophil migration, both in vitro and in vivo. It was found that human APC possesses an Arg-Gly-Asp (RGD) sequence, which is critical for the inhibition. Mutation of this sequence abolished both integrin binding and inhibition of neutrophil migration. In addition, an RGD peptide enhanced the survival of septic mice. Thus, leukocyte integrins are cellular receptors for rhAPC, and their interaction decreases neutrophil recruitment into tissues, providing a mechanism by which rhAPC protects from sepsis.

Provided herein are variant APC polypeptides and variant APC polypeptide fragments. Such variants contain a RGD motif and are selected for their ability to bind integrins, such as β1 and/or β3 integrins. Optionally, the variant APC polypeptides bind with higher affinity to the integrins than wild-type APC. Specifically, provided are APC polypeptides comprising one or more amino acid substitutions. There are a variety of sequences that are disclosed on Genbank, at www.pubmed.gov and these sequences are herein incorporated by reference in their entireties as are individual subsequences or fragments contained therein. For example, the amino acid sequence of human protein C can be found at GenBank Accession No. NP_000303.1 and P04070. Human protein C (SEQ ID NO:2) is synthesized as a single chain precursor, which is cleaved into a light chain and a heavy chain held together by a disulfide bond. Activated protein C is shown as SEQ ID NO: 1. Thus, provided are polypeptides of an APC comprising one or more amino acid substitutions selected from the group consisting of K146R, D172N, C212R, K146G, R147G, R177G and combinations thereof. Optionally, the APC comprises the amino acid substitution K146R or D172N. Optionally, the APC comprises the amino acid substitutions K146G and R147G. Optionally, the APC comprises the amino acid substitutions R177G, K146G and R147G. Optionally, the APC comprises the amino acid substitutions C212R, K146G and R147G. Optionally, the APC comprises the amino acid substitutions C212R and R177G. Optionally, the APC
further comprises the amino acid substitutions KKK191-193AAA and/or RR229/230AA.

Optionally, the APC comprises SEQ ID NO:1. Thus, provided are polypeptides of SEQ ID NO:1 with one or more amino acid substitutions. The amino acid substitutions include K146R, D172N, C212R, K146G, R147G, R177G and combinations thereof. Optionally, the polypeptides further include amino acid substitutions RR229/230AA and/or KKK191-193AA. Thus, provided are polypeptides comprising SEQ ID NOs:3-32, 42 and 43.

As used herein, the terms peptide, polypeptide, protein or peptide portion are used broadly herein to mean two or more amino acids linked by a peptide bond. The term fragment is used herein to refer to a portion of a full-length polypeptide or protein. It should be recognized that the term polypeptide is not used herein to suggest a particular size or number of amino acids comprising the molecule and that a peptide of the invention can contain up to several amino acid residues or more.

A polypeptide comprising a fragment of the variant APC polypeptides are provided. Thus, provided are fragments of SEQ ID NO:1 comprising one or more amino acid substitutions. Thus, the fragments include one or more of the amino acid substitutions selected from K146R, D172N, C212R, K146G, R147G, R177G and combinations thereof. Optionally, the fragments further include amino acid substitutions RR229/230AA and/or BCKK191-193AA. The fragments also include an RGD motif. It is understood that the term fragment includes a functional fragment. A functional fragment of a variant APC is selected for its ability to bind integrins, such as β1 and/or β3 integrins, for example, as shown in the Examples.

As discussed above, the polypeptides provided herein, including fragments, have a desired function. The polypeptides as described herein selectively bind β1 and/or β3 integrins. By binding is meant a detectable binding of at least about 1.5 times the background of the assay method. For selective or specific binding such a detectable binding can be detected for a given agent but not a control antigen or agent. Optionally, the polypeptides described herein bind with similar or higher affinity than wild-type APC (i.e., SEQ ID NO: 1). By binding with higher affinity is meant a detectable binding at least about 1.5 times higher than the binding affinity of a control (e.g., wild type) for a particular assay method. The polypeptides are tested for their desired activity using the in vitro assays described herein, or by analogous methods,
after which their therapeutic, diagnostic or other purification activities are tested according to known testing methods.

As with all peptides, polypeptides, and proteins, including fragments thereof, it is understood that additional modifications in the amino acid sequence of the variant APC polypeptides can occur that do not alter the nature or function of the peptides, polypeptides, or proteins. Such modifications include conservative amino acid substitutions and are discussed in greater detail below.

The polypeptides described herein can be further modified so long as the desired function is maintained. It is understood that one way to define any known modifications and derivatives or those that might arise, of the disclosed genes and proteins herein is through defining the modifications and derivatives in terms of identity to specific known sequences. Specifically disclosed are polypeptides which have at least, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 percent identity to the APC and APC variants provided herein. For example, provided are polypeptides which have at least, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 percent identity to one of SEQ ID NOs:3-32. Those of skill in the art readily understand how to determine the identity of two polypeptides. For example, the identity can be calculated after aligning the two sequences so that the identity is at its highest level.


The same types of identity can be obtained for nucleic acids by, for example, the algorithms disclosed in Zuker, M. Science 244:48-52, 1989, Jaeger et al. Proc. Natl. Acad. Sci. USA 86:7706-7710, 1989, Jaeger et al. Methods Enzymol. 183:281-306, 1989, which are herein incorporated by reference for at least material related to nucleic acid alignment. It is understood that any of the methods typically can be used
and that in certain instances the results of these various methods may differ, but the skilled artisan understands if identity is found with at least one of these methods, the sequences would be said to have the stated identity, and be disclosed herein.

Protein modifications include amino acid sequence modifications. Modifications in amino acid sequence may arise naturally as allelic variations (e.g., due to genetic polymorphism) or may be produced by human intervention (e.g., by mutagenesis of cloned DNA sequences), such as induced point, deletion, insertion and substitution mutants. These modifications can result in changes in the amino acid sequence, provide silent mutations, modify a restriction site, or provide other specific mutations. Post-translational modifications can include variations in the type or amount of carbohydrate moieties of the protein core or any fragment or derivative thereof. Amino acid sequence modifications typically fall into one or more of three classes: substitutional, insertional or deletional modifications. Insertions include amino and/or carboxyl terminal fusions as well as intrasequence insertions of single or multiple amino acid residues. Insertions ordinarily will be smaller insertions than those of amino or carboxyl terminal fusions, for example, on the order of one to four residues. Deletions are characterized by the removal of one or more amino acid residues from the protein sequence. Typically, no more than about from 2 to 6 residues are deleted at any one site within the protein molecule. Amino acid substitutions are typically of single residues, but can occur at a number of different locations at once; insertions usually will be on the order of about from 1 to 10 amino acid residues; and deletions will range about from 1 to 30 residues. Deletions or insertions preferably are made in adjacent pairs, i.e. a deletion of 2 residues or insertion of 2 residues. Substitutions, deletions, insertions or any combination thereof may be combined to arrive at a final construct. The mutations must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure. Substitutional modifications are those in which at least one residue has been removed and a different residue inserted in its place. Such substitutions generally are made in accordance with the following Table 1 and are referred to as conservative substitutions.
TABLE 1: Amino Acid Substitutions

<table>
<thead>
<tr>
<th>Amino Acid</th>
<th>Substitutions (others are known in the art)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ala</td>
<td>Ser, Gly, Cys</td>
</tr>
<tr>
<td>Arg</td>
<td>Lys, Gln, Met, He</td>
</tr>
<tr>
<td>Asn</td>
<td>Gln, His, Glu, Asp</td>
</tr>
<tr>
<td>Asp</td>
<td>Glu, Asn, Gln</td>
</tr>
<tr>
<td>Cys</td>
<td>Ser, Met, Thr</td>
</tr>
<tr>
<td>Gln</td>
<td>Asn, Lys, Glu, Asp</td>
</tr>
<tr>
<td>Glu</td>
<td>Asp, Asn, Gln</td>
</tr>
<tr>
<td>Gly</td>
<td>Pro, Ala</td>
</tr>
<tr>
<td>His</td>
<td>Asn, Gln</td>
</tr>
<tr>
<td>He</td>
<td>Leu, Val, Met</td>
</tr>
<tr>
<td>Leu</td>
<td>He, Val, Met</td>
</tr>
<tr>
<td>Lys</td>
<td>Arg, Gln, Met, He</td>
</tr>
<tr>
<td>Met</td>
<td>Leu, He, Val</td>
</tr>
<tr>
<td>Phe</td>
<td>Met, Leu, Tyr, Trp, His</td>
</tr>
<tr>
<td>Ser</td>
<td>Thr, Met, Cys</td>
</tr>
<tr>
<td>Thr</td>
<td>Ser, Met, Val</td>
</tr>
<tr>
<td>Trp</td>
<td>Tyr, Phe</td>
</tr>
<tr>
<td>Tyr</td>
<td>Trp, Phe, His</td>
</tr>
<tr>
<td>Val</td>
<td>He, Leu, Met</td>
</tr>
</tbody>
</table>

Modifications, including the specific amino acid substitutions, are made by known methods including the methods described in the Examples below. By way of example, modifications are made by site specific mutagenesis of nucleotides in the DNA encoding the protein, thereby producing DNA encoding the modification, and thereafter expressing the DNA in recombinant cell culture. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, for example M13 primer mutagenesis and PCR mutagenesis.

Nucleic acids that encode the aforementioned variant polypeptide sequences and fragments thereof are also disclosed. Thus, provided is a nucleic acid sequence encoding an APC comprising one or more amino acid substitutions selected from the group consisting of K146R, D172N, C212R, K146G, R147G, R177G and
combinations thereof. Optionally, the encoded APC comprises the amino acid substitutions K146R or D172N. Optionally, the encoded APC comprises the amino acid substitutions K146G and R147G. Optionally, the encoded APC comprises the amino acid substitutions R177G, K146G and R147G. Optionally, the encoded APC comprises the amino acid substitutions C212R, K146G and R147G. Optionally, the encoded APC comprises the amino acid substitutions C212R and R177G. Optionally, the encoded APC comprises an RGD motif. Optionally, the encoded APC further comprises the amino acid substitutions KKK191-193AAA and/or RR229/230AA.

Thus, provided are nucleic acids encoding SEQ ID NOs: 1-32, 42 and 43. These nucleic acid sequences include all degenerate sequences related to a specific protein sequence, i.e. all nucleic acids having a sequence that encodes one particular protein sequence as well as all nucleic acids, including degenerate nucleic acids, encoding the disclosed variants and derivatives of the protein sequences. Thus, while each particular nucleic acid sequence may not be written out herein, it is understood that each and every sequence is in fact disclosed and described herein through the disclosed protein sequence.

Isolated nucleic acid molecules can be produced by standard techniques. For example, polymerase chain reaction (PCR) techniques can be used to obtain an isolated nucleic acid containing a nucleotide sequence described herein. Various PCR methods are described, for example, in PCR Primer: A Laboratory Manual, Dieffenbach and Dveksler, eds., Cold Spring Harbor Laboratory Press, 1995. Various PCR strategies also are available by which the site-specific nucleotide sequence modifications described herein can be introduced into a template nucleic acid. Optionally, isolated nucleic acids are chemically synthesized, either as a single nucleic acid molecule (e.g., using automated DNA synthesis in the 3’ to 5’ direction using phosphoramidite technology) or as a series of oligonucleotides. For example, one or more pairs of long oligonucleotides (e.g., >100 nucleotides) can be synthesized that contain the desired sequence, with each pair containing a short segment of complementarity (e.g., about 15 nucleotides) such that a duplex is formed when the oligonucleotide pair is annealed. DNA polymerase is used to extend the oligonucleotides, resulting in a single, double-stranded nucleic acid molecule per oligonucleotide pair, which then can be ligated into a vector. Isolated nucleic acids
disclosed herein also can be obtained by mutagenesis of, e.g., a naturally occurring DNA.

Also provided are expression vectors comprising the disclosed nucleic acids, wherein the nucleic acids are operably linked to an expression control sequence. Suitable vector backbones include, for example, those routinely used in the art such as plasmids, viruses, artificial chromosomes, BACs, YACs, or PACs. Suitable expression vectors include, without limitation, plasmids and viral vectors derived from, for example, bacteriophage, baculoviruses, and retroviruses. Numerous vectors and expression systems are commercially available from such corporations as Novagen (Madison, WI), Clontech (Palo Alto, CA), Stratagene (La Jolla, CA), and Invitrogen/Life Technologies (Carlsbad, CA). Vectors typically contain one or more regulatory regions. Regulatory regions include, without limitation, promoter sequences, enhancer sequences, response elements, protein recognition sites, inducible elements, protein binding sequences, 5’ and 3’ untranslated regions (UTRs), transcriptional start sites, termination sequences, polyadenylation sequences, and introns.

Preferred promoters controlling transcription from vectors in mammalian host cells may be obtained from various sources, for example, the genomes of viruses such as polyoma, Simian Virus 40 (SV40), adenovirus, retroviruses, hepatitis B virus and most preferably cytomegalovirus, or from heterologous mammalian promoters, e.g. beta actin promoter or EF1 promoter, or from hybrid or chimeric promoters (e.g., cytomegalovirus promoter fused to the beta actin promoter). The early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment which also contains the SV40 viral origin of replication. The immediate early promoter of the human cytomegalovirus is conveniently obtained as a HindIII E restriction fragment. Of course, promoters from the host cell or related species also are useful herein.

Enhancer generally refers to a sequence of DNA that functions at no fixed distance from the transcription start site and can be either 5’ or 3’ to the transcription unit. Furthermore, enhancers can be within an intron as well as within the coding sequence itself. They are usually between 10 and 300 bp in length, and they function in cis. Enhancers usually function to increase transcription from nearby promoters. Enhancers can also contain response elements that mediate the regulation of
transcription. While many enhancer sequences are now known from mammalian
genes (globin, elastase, albumin, fetoprotein and insulin), typically one will use an
eenhancer from a eukaryotic cell virus for general expression. Preferred examples are
the SV40 enhancer on the late side of the replication origin, the cytomegalovirus early
promoter enhancer, the polyoma enhancer on the late side of the replication origin,
and adenovirus enhancers.

Optionally, the promoter and/or enhancer region can act as a constitutive
promoter and/or enhancer to maximize expression of the region of the transcription
unit to be transcribed. In certain constructs the promoter and/or enhancer region be
active in all eukaryotic cell types, even if it is only expressed in a particular type of
cell at a particular time. A preferred promoter of this type is the CMV promoter.
Other preferred promoters are SV40 promoters, cytomegalovirus (plus a linked intron
sequence), beta-actin, elongation factor-1 (EF-1) and retroviral vector LTR.

The vectors also can include, for example, origins of replication, scaffold
attachment regions (SARs), and/or markers. A marker gene can confer a selectable
phenotype, e.g., antibiotic resistance, on a cell. This marker product is used to
determine if the gene has been delivered to the cell and once delivered is being
expressed. Examples of marker genes include the E. coli lacZ gene, which encodes β
galactosidase, green fluorescent protein (GFP), and luciferase. Examples of suitable
selectable markers for mammalian cells are dihydrofolate reductase (DHFR),
thymidine kinase, neomycin, neomycin analog G418, hygromycin, and puromycin.
When such selectable markers are successfully transferred into a mammalian host
cell, the transformed mammalian host cell can survive if placed under selective
pressure. In addition, an expression vector can include a tag sequence designed to
facilitate manipulation or detection (e.g., purification or localization) of the expressed
polypeptide. Tag sequences, such as green fluorescent protein (GFP), glutathione S-
transferase (GST), polyhistidine, c-myc, hemagglutinin, or Flag™ tag (Kodak, New
Haven, CT) sequences typically are expressed as a fusion with the encoded
polypeptide. Such tags can be inserted anywhere within the polypeptide, including at
either the carboxyl or amino terminus.

Further provided are cultured cells comprising the expression vectors. Such
expression vectors and cultured cells can be used to make the provided polypeptides.
Thus, the expression vectors disclosed herein containing the above described nucleic
acid sequences can be used, for example, to transfect or transduce either prokaryotic (e.g., bacterial) cells or eukaryotic cells (e.g., yeast, insect, or mammalian) cells. Such cells can then be used, for example, for large or small scale in vitro production of the provided variant APC polypeptides and fragments thereof. Such methods involve culturing the cells under conditions for production of the polypeptides and isolating the polypeptides from the cells or from the culture medium.

Provided herein are compositions containing the provided polypeptides or nucleic acids and a pharmaceutically acceptable carrier. The herein provided compositions are administered in vitro or in vivo. By pharmaceutically acceptable carrier is meant a material that is not biologically or otherwise undesirable, i.e., the material is administered to a subject, e.g., with a variant APC, without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained. The carrier is selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject.

Suitable carriers and their formulations are described in Remington: The Science and Practice of Pharmacy, 21st Edition, David B. Troy, ed., Lippicott Williams & Wilkins (2005). Typically, an appropriate amount of a pharmaceutically-acceptable salt is used in the formulation to render the formulation isotonic.

Examples of the pharmaceutically-acceptable carriers include, but are not limited to, sterile water, saline, buffered solutions like Ringer's solution, and dextrose solution. The pH of the solution is generally from about 5 to about 8 or from about 7 to about 7.5. Other carriers include sustained release preparations such as semipermeable matrices of solid hydrophobic polymers containing the immunogenic polypeptides.

Matrices are in the form of shaped articles, e.g., films, liposomes or microparticles. Certain carriers may be more preferable depending upon, for instance, the route of administration and concentration of composition being administered. Carriers are those suitable for administration of the agent, e.g., the variant APC polypeptide, to humans or other subjects.

The compositions are administered via any of several routes of administration, including, for example, topically, orally, parenterally, intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, transdermally, intrahepatically, intracranially, nebulization/inhalation, or by instillation via bronchoscopy.
Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives are optionally present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.

Optionally, the composition is administered by oral inhalation, nasal inhalation or intranasal mucosal administration. As used herein, these terms mean delivery of the compositions into the nose and nasal passages through one or both of the nares and can comprise delivery by a spraying mechanism or droplet mechanism, or through aerosolization of the nucleic acid or vector. Administration of the compositions by inhalant is through the nose or mouth via delivery by a spraying or droplet mechanism. For example, in the form of an aerosol. Delivery is optionally directly to any area of the respiratory system (e.g., lungs) via intubation.

Formulations for topical administration include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like are optionally necessary or desirable.

Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders are optionally desirable.

Provided herein are methods of treating sepsis in a subject. Such methods include administering one or more of the provided nucleic acids, one or more of the provided polypeptides, and combinations thereof to the subject. Optionally, the nucleic acids and/or polypeptides are contained within a pharmaceutical composition as described above.
Optionally, the nucleic acid is administered by a vector comprising the nucleic acid. There are a number of compositions and methods which can be used to deliver nucleic acids to cells, either in vitro or in vivo via, for example, expression vectors. These methods and compositions can largely be broken down into two classes: viral based delivery systems and non-viral based delivery systems. Such methods are well known in the art and readily adaptable for use with the compositions and methods described herein.

As used herein, plasmid or viral vectors are agents that transport the disclosed nucleic acids into the cell without degradation and include a promoter yielding expression of the gene in the cells into which it is delivered. Viral vectors are, for example, Adenovirus, Adeno-associated virus, Herpes virus, Vaccinia virus, Polio virus, Sindbis and other RNA viruses, including these viruses with the HIV backbone. Also preferred are any viral families which share the properties of these viruses which make them suitable for use as vectors. Retroviral vectors, in general, are described by Verma, LM., Retroviral vectors for gene transfer. In Microbiology - 1985, American Society for Microbiology, pp. 229-232, Washington, (1985), which is incorporated by reference herein for the vectors and methods of making them. The construction of replication-defective adenoviruses has been described (Berkner et al., J. Virology 61:1213-1220 (1987); Massie et al., Mol. Cell. Biol. 6:2872-2883 (1986); Haj-Ahmad et al., J. Virology 51:261-271A (1986); Davidson et al., J. Virology 61:1226-1239 (1987); Zhang et al., BioTechniques 15:868-872 (1993)). The benefit of the use of these viruses as vectors is that they are limited in the extent to which they can spread to other cell types, since they can replicate within an initial infected cell, but are unable to form new infectious viral particles. Recombinant adenoviruses have been shown to achieve high efficiency after direct, in vivo delivery to airway epithelium, hepatocytes, vascular endothelium, CNS parenchyma and a number of other tissue sites. Other useful systems include, for example, replicating and host-restricted non-replicating vaccinia virus vectors.

The provided polypeptides or nucleic acids can be delivered via virus like particles. Virus like particles (VLPs) consist of viral protein(s) derived from the structural proteins of a virus. Methods for making and using virus like particles are described in, for example, Garcea and Gissmann, Current Opinion in Biotechnology 15:513-7 (2004).
The provided polypeptides can be delivered by subviral dense bodies (DB). DBs transport proteins into target cells by membrane fusion. Methods for making and using DBs are described in, for example, Pepperl-Klindworth et al., Gene Therapy 10(3):278-84 (2003).

The provided polypeptides can be delivered by tegument aggregates. Methods for making and using tegument aggregates are described in International Publication No. WO 2006/110728.

Optionally, the pharmaceutical composition comprises an effective amount or effective dosage of the provided polypeptides or nucleic acids. An effective amount of the pharmaceutical composition comprises a dosage between about 0.01 mg per kg body weight of the subject up to about 100 mg per kg body weight of the subject. The dosage can be, for example, from about 0.01, 0.025, 0.05, 0.1, 0.5 to about 25, 50, 75, or 100 mg/kg. Optionally, the pharmaceutical composition is administered from 0.01 to 50 µg/kg/hr. Optionally, the pharmaceutical composition is administered from 0.1 to 25 µg/kg/hr. Optionally, the pharmaceutical composition is administered as an intravenous infusion. Optionally, 2.5 to 25 mg of the pharmaceutical composition is administered as an intravenous infusion. Doses are administered in one or more dose administrations daily, for one or several days.

Also provided herein is a method of treating sepsis in a subject comprising administering to the subject one or more RGD-containing peptides. Optionally, the RGD-containing peptide is a cyclic RGD-containing peptide. Optionally, the RGD-containing peptide is selected from the group consisting of c[RGDD(tot-butylglycine)(m-ammonomethylbenzoic acid)]; c[(3-mercaptopropionic acid)RGDD(ter t-butylglycine)C]-NH₂; G-c[(penicillamine)RARGDNPC]-A; acetyl-c[(penicillamine)-O-methyltyrosine-ARGDN(tetrahydroisoquinoline-3-carboxylic acid)C]-NH₂, and acetylphenylalanine-c[CRGDTFC]-NH₂. Optionally, the RGD-containing peptide is acetyl-c[(penicillamine)-O-methyltyrosine-ARGDN(tetrahydroisoquinoline-3-carboxylic acid)C]-NH₂. The RGD containing peptides can be formulated in a pharmaceutical composition as described above.

The methods optionally include administering one or more other therapeutic or prophylactic regimens. Thus, the provided methods can further comprise the step of administering a second therapeutic agent to the subject. The second therapeutic agent is, optionally, drotrecogin alfa (activated) (Xigris®, Eli Lilly, Indianapolis, IN).
Optionally, the second therapeutic agent is SEQ ID NO:1. Optionally, the second therapeutic agent is an RGD-containing peptide. As used throughout, a therapeutic agent is a compound or composition effective in ameliorating a pathological condition. Illustrative examples of other therapeutic agents include, but are not limited to, antibiotics, anti-inflammatory agents, vasopressors, pain killers, and sedatives. Optionally, the anti-inflammatory agent is a corticosteroid. Optionally, the therapeutic agent is an antibody that blocks β1 or β3 integrin activity.

Anti-inflammatory agents, that may be administered in combination with the provided compositions include, but are not limited to steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone, azathioprine, FK-506 (Fujisawa Pharmaceuticals, Deerfield, IL), 15 deoxyxypersgualin, and other immunosuppressive agents that act by suppressing the function of responding immune cells (including, for example, T cells), directly (e.g., by acting on the immune cell) or indirectly (by acting on other mediating cells). Immunosuppressive agents also include, ORTHOCLONE® (OKT3) (Ortho Biotech, Raritan, NJ), SANDIMMUNE® ORAL (cyclosporine) (Sandoz Pharmaceuticals, Hanover, NJ), PROGRAF® (tacrolimus) (Fujisawa Pharmaceuticals, Deerfield, IL), CELLCEPT® (mycophenolate) (Roche Pharmaceuticals, Nutley, NJ), azathioprine, glucorticosteroids, and RAPAMUNE® (sirolimus) (Wyeth, Collegeville, PA).

Any of the aforementioned second therapeutic agents or treatment regimes can be used in any combination with the compositions described herein. Combinations are administered either concomitantly (e.g., as an admixture), separately but simultaneously (e.g., via separate intravenous lines into the same subject), or sequentially (e.g., one of the compounds or agents is given first followed by the second). Thus, the term combination is used to refer to either concomitant, simultaneous, or sequential administration of two or more agents.

The terms effective amount and effective dosage are used interchangeably. The term effective amount is defined as any amount necessary to produce a desired physiologic response. Effective amounts and schedules for administering the compositions are determined empirically. The dosage ranges for the administration of the compositions are those large enough to produce the desired effect in which the symptoms or disorder are affected. The dosage is not so large as to cause substantial adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the
like. Generally, the dosage varies with the age, condition, sex, type of disease and extent of the disease in the patient, route of administration, or whether other drugs are included in the regimen, and is determined by one of skill in the art. The dosage is optionally adjusted by the individual physician in the event of any contraindications.

Also provided are methods of screening for polypeptides with enhanced APC activity. The method includes contacting a polypeptide to be tested with a cell expressing one or both of β1 integral and β3 integral, wherein the polypeptide to be tested comprises APC or a fragment thereof comprising one or more amino acid substitutions, and determining whether the polypeptide to be tested binds to the β1 integrin or β3 integrin better than a control APC or fragment thereof, wherein binding better than the control indicates the polypeptide to be tested has enhanced APC activity. Optionally, the contacting step includes contacting a cell expressing the polypeptide to be tested with the cell expressing one or both of β1 integrin and β3 integrin. Optionally, the polypeptide to be tested is made by mutagenizing APC or a fragment thereof using, e.g., error-prone PCR. Optionally, the control APC comprises SEQ ID NO: 1.

Also provided is a method of screening for an agent for treatment of sepsis including contacting the agent to be screened with a cell expressing one or both of β1 integrin and β3 integrin, contacting an APC or fragment thereof with the cell, and determining whether the agent competes with APC for binding to the β1 integrin or β3 integrin. If the agent competes with APC for binding, this indicates the agent is suitable for treatment of sepsis. Optionally, the APC comprises SEQ ID NO: 1. Optionally, the APC or fragment thereof comprises an RGD motif.

The polypeptide, nucleic acids, compositions and combinations thereof described herein can be assembled in kits. Thus, provided are kits comprising one or more of the provided nucleic acids and a container. Also provided are kits comprising one or more of the provided polypeptides and a container. Suitable containers include vials, packets, or intravenous bags. Optionally, the kit includes measured amounts of a pharmaceutically acceptable composition comprising the nucleic acid or polypeptide. The kit can also include instruments useful in administration, such as needles, syringes, tubing, catheters, bandages, and tape. The kits can also include instructions for use.
As used throughout, by a subject is meant an individual. Thus, the subject can include, for example, domesticated animals, such as cats and dogs, livestock (e.g., cattle, horses, pigs, sheep, and goats), laboratory animals (e.g., mice, rabbits, rats, and guinea pigs), mammals, non-human mammals, primates, non-human primates, rodents, birds, reptiles, amphibians, fish, and any other animal. The subject can be a mammal such as a primate or a human. The term subject also includes individuals of different ages. Thus, a subject includes an infant, child, teenager or adult.

As used herein the terms treatment, treat or treating refers to a method of reducing the effects of a disease or condition or symptom of the disease or condition. Thus in the disclosed method, treatment can refer to a 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% reduction in the severity of an established disease or condition or symptom of the disease or condition. For example, a method for treating a disease is considered to be a treatment if there is a 5% reduction in one or more symptoms of the disease in a subject as compared to control. Thus the reduction can be a 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100% or any percent reduction in between 10 and 100 as compared to native or control levels. It is understood that treatment does not necessarily refer to a cure or complete ablation of the disease, condition or symptoms of the disease or condition.

As used herein, the terms prevent, preventing and prevention of a disease or disorder refers to an action, for example, administration of a therapeutic agent, that occurs before or at about the same time a subject begins to show one or more symptoms of the disease or disorder, which inhibits or delays onset or exacerbation of one or more symptoms of the disease or disorder. As used herein, references to decreasing, reducing, or inhibiting include a change of 5, 10, 20, 30, 40, 50, 60, 70, 80, 90 percent or greater as compared to a control level. Such terms can include but do not necessarily include complete elimination.

Disclosed are materials, compositions, and components that can be used for, can be used in conjunction with, can be used in preparation for, or are products of the disclosed methods and compositions. These and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutations of these compounds may not be explicitly disclosed, each is specifically contemplated and described herein. For
example, if a substitution or modification is disclosed and discussed and a number of other substitutions or modifications that can be made, each and every combination and permutation can be combined, and the modifications that are possible are specifically contemplated unless specifically indicated to the contrary. Likewise, any subset or combination of these is also specifically contemplated and disclosed. This concept applies to all aspects of this disclosure including, but not limited to, steps in methods of using the disclosed compositions. Thus, if there are a variety of additional steps that can be performed, it is understood that each of these additional steps can be performed with any specific method steps or combination of method steps of the disclosed methods, and that each such combination or subset of combinations is specifically contemplated and should be considered disclosed.

Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application.

A number of aspects have been described. Nevertheless, it will be understood that various modifications may be made. Furthermore, when one characteristic or step is described it can be combined with any other characteristic or step herein even if the combination is not explicitly stated. Accordingly, other aspects are within the scope of the claims.

Examples

Example 1. Direct binding of activated protein C to integrins and its protective effects in sepsis.

Materials and Methods

Reagents. Recombinant Human APC (rhAPC) was obtained from Eli Lilly (Indianapolis, IN). The protein C mutant containing Glu substitutions in place of Asp-222 (D222E) was constructed by overlap extension PCR. The inner complementary primers were 5'-'GACCAGCGGGAGAGGCCCTGGCGAGGTG-S' (SEQ ID NO:33) and 5'-'CACCTGCCAGGGCTCTCTCCCGCTGTCGTC-S' (SEQ ID NO:34). The outer primers corresponded to vector plasmid cDNA (pRC/CMV) bases 837 to 856 and 1038 to 1065. The second round PCR product was digested with HindIII and XbaI, and inserted into pcDNA 3.1(+)/Hygro vector (Invitrogen, Carlsbad, CA). The mutant zymogen was expressed in HEK293 cells, purified and converted to activated protein C by thrombin, and separated from thrombin by an
FPLC Mono Q column as described (Bae et al., Proc Natl Acad Sci U S A 104:2867 (2007)).

DNA Plasmids and Constructs. For hEPCR-mCFP, PCR extensions were performed on wild type hEPCR cDNAin pSVzeo as a template. The upstream primer 5'-

ATATAAAGCTTGCCACCATGTTGACAACATTGCTGCC-S' (SEQ ID NO:35)

with a HindIII site and the downstream primer 5'-

TATATACCGGTCCACATCGCCGTCCACCTGTGC-3' (SEQ ID NO:36) with an Agel site were used with hEPCR-pSVzeo. After digestion with HindIII and Agel, the PCR fragment was inserted into HindIII and Agel digested pECFP.

For βl-mYFP with 5 amino acid residue linker, PCR extension was performed using wild type βl subunit cDNA (Genbank Accession No. BC020057) as a template with the upstream primer 5'-

ATATACTCGAGGCACTGAATTACAACCAAATTTT-S'(SEQ ID NO:37)

containing Xhol site and the downstream primer 5'-

TATATACCGGTCTTTTCCCTCTACTTCGGAT-S'(SEQ ID NO:38) containing Agel site. After digestion with Xhol and Agel, PCR product and mYFP then ligated to generate βl(5)-mYFP containing 5 amino acid residue linker of GPVAT.

Monomeric mCFP and mYFP mutants were generated by replacing Leu-221 at the crystallographic dimer interface with a Lys.

Human neutrophil preparation. Blood was collected from healthy volunteers via antecubital vein puncture in heparin or EDTA-containing vacutainers. Granulocytes and erythrocytes were separated from whole blood by centrifugation through a Histopaque 1077 (Sigma, St. Louis, MO) density gradient. The cell suspension containing neutrophils was collected and washed with HBSS-/ (without calcium or magnesium) at 1250 rpm for 10 min at 4°C. Remaining erythrocytes were removed by hypotonic lysis, yielding a neutrophil purity of greater than 98%. Neutrophils were resuspended in cold HBSS-/ for experimentation.

Under-agarose migration assay. Delta T dishes (Bioptechs, Butler, PA) were coated with fibronectin (FN). Plates were then rinsed with the appropriate media and allowed to air-dry. Molten agarose (Seakem GTG, FMC Bioproducts, Rockland, ME) was prepared as described (Harler et al., J Immunol., 162:6792 (1999)). Two milliliters of the resulting gel was added to each dish and allowed to solidify at 4°C for 5 min. Three wells that were 2 mm apart were prepared in the agarose using a template and a
beveled punch that was coated with polymixin B. Care was taken to ensure that the plate bottom was not scratched. Punch sections were removed with an aspirator, and the gel was then equilibrated for one hour at 37°C. The wells were then aspirated and loaded with 30 ml of one of the following: PBS (left well), a suspension containing approximately 200,000 cells (middle well), or a solution containing 5 pmol of fMLP (right well). A subset of cells was treated with 10 µg/ml rhAPC at 37°C for 20 min prior to being loaded into the wells. The dishes were incubated for 60 min at 37°C, and then fixed with 10% buffered formalin. Counts were then made of the number of cells that had migrated 1 mm towards the right well (towards fMLP, directional migration), 0.5 mm towards the left and right wells ("straddle"), and 1 mm towards the left well (random migration). The experiments were repeated three times per condition.

Measurement of random migration and micropipette assay. Delta T dishes were coated with human FN (50 µg/ml, BD Biosciences, San Jose, CA) for overnight at 4°C and then for 4 h at room temperature. Plates were then rinsed with L-15 media. Human neutrophils (approximately 500,000) were incubated, in the presence or absence of 10 µg/ml of wild type rhAPC or mutant RGE-APC in 500 µl L-15 media containing 2 mg/ml glucose for 20 min at 37°C. The cells were then added to FN-coated dishes in 1.5 ml of L-15 with 2 mg/ml of glucose. For neutrophil live cell staining, 2 µM Green Cell Tracker CMFDA (5-chloromethylfluorescein diacetate; Molecular Probes, Carlsbad, CA) was used. Temperature was maintained at 37°C throughout the experiment using a FCS2 live-cell imaging chamber (Bioptechs, Butler, PA). Images were acquired for 30 to 60 minutes under a 10x objective lens using a Nikon TE-2000U inverted microscope. Phase contrast images were acquired every 5 seconds and fluorescence images every 30 seconds. Cell paths were traced using MetaVue™ imaging software (Molecular Devices Corporation, Downingtown, PA).

Random migration was investigated by adding fMLP or IL-8 to media at a final concentration of 10^{-8}M and analyzed by manually tracing the outline of each cell in selected frames (i.e., at 50 second intervals). The x and y coordinates of each cell were measured using ImageJ software and were corrected so that the starting position was x = 0 and y = 0.
Directional migration was investigated using a micropipette assay to analyze the dynamics of neutrophil migration on different integrin ligands. Sterile Femtotips II micropipette tips (Eppendorf, Westbury, NY) were loaded with 5 µl of 1µM fMLP and then placed on the bottom of FN-coated delta T dishes that had been pre-warmed to 37°C. Image acquisition began within 2 minutes of tip placement.

The time-lapsed images of migrating neutrophils were taken under phase contrast microscopy. Each image was thresholded and binarized based on brightness to define the centroids of the neutrophils. The closest centroids between consecutive images were linked as a trajectory under the assumption that these centroids were made by the same neutrophil. The maximum distance between the closest centroids was also defined to preclude the artifacts due to cells moving into and out of the field of view. To demonstrate the randomness of chemokinesis and the distances that each cell travel, the starting points of the trajectories of the neutrophils were translated to the origin.

**FACS analysis.** Neutrophils were pretreated with 10 µg/ml of rhAPC in HBS (20 mM Hepes, pH7.5, 140 mM NaCl) + 1 mM Ca²⁺ and 1 mM Mg²⁺, or +3 mM Ca²⁺ and 0.6 mM Mg²⁺ for 30 min at 37°C. LIBS mAbs (B44 and D3) were added 5 minutes prior to fixation with 3.7% formaldehyde for 10 minutes at room temperature. Then cells were washed and incubated with PE-labeled goat anti-mouse IgG for 30 minutes at 4°C in the dark. Cells were then washed and resuspended in PBS for FACS analysis.

**Neutrophil Adhesion Assays.** The adhesion assay was carried out essentially as described (Vorup-Jensen et al., PNAS 102: 1614 (2005)). Cover slips were coated with FN in coating buffer (150 mM NaCl/20 mM Tris-HCl, pH 9.0) for over night at 4°C and for 4 hours at room temperature. Residual binding sites were blocked by incubation of the wells with 0.05% (wt/vol) polyvinylpyrrolidone in PBS for 30 minutes at room temperature. 2.5 x 10⁵/250 µl of neutrophils were suspended in L15 medium plus 2mg/ml glucose and pretreated for 15 minutes at 37°C with 10 µg/ml rhAPC, 50 µg/ml human EPCR blocking mAb (RCR-252), or 10 µg/ml Gla-less rhAPC (Enzyme Research Lab., IN). The cover slips were aspirated, and washed with L15 medium. 250 µl of L15/2mg/ml glucose medium containing 10 µg/ml rhAPC, 50 µg/ml human EPCR blocking mAb, or 10 µg/ml Gla-less rhAPC, with/without 20 nM fMLP was placed on each cover slip and prewarmed for 15 minutes at 37°C. Cells (250 µl) were then immediately added, and further incubated at 37°C for 15 minutes.
Unbound cells were then washed with warm L15 medium. The bound cells were then fixed with formaldehyde. For each experimental condition from three independent donors, five random phase-contrast images were obtained, and the number of cells in each well was scored from printed micrographs.

*Integrin ligand binding assay.* The solid phase binding assay was performed using purified soluble human αβ1, αδβ1, and αγβ3 (US Biological, Swampscott, MA). Two (2) μg/ml of soluble integrins were added to microtiter wells for capture with immobilized monoclonal antibody against β1 or β3 subunits (mAb TS2/6 for β1 and mAb BBIO (Chemicon, Temecula, CA) for β3 integrins). 48 hours after co-transfection with hEPCR-mCFP and βl-mYFP DNA

RGE-APC, or 5 μg/ml of human FN was incubated in the presence of 1 mM Ca²⁺ and Mg²⁺ plus 1 mM Mn²⁺ for 1 h at room temperature. After washing, bound APC was chromogenically detected by peroxidase-streptavidin conjugate anti-PC (Diapharma, West Chester, OH) or chromogenic substrate S-2366 (Diapharma, West Chester, OH). To minimize dissociation, all wash buffers contained 1 mM Mn²⁺, and <15 minutes elapsed between the end of binding and beginning of color development. Functional blocking antibodies for integrins were from Chemicon (Temecula, CA).

*Intracellular Ca²⁺ measurement.* 1x10⁷ cells/ml of human neutrophils were labeled with 5μM Fluo-4 AM (Molecular Probes, Eugene, OR) at 37°C for 30 minutes, then at room temperature for an additional 5 to 10 minutes. After washing twice, cells were resuspended to 4x10⁶ cells/ml (6ml) in F15 and incubated at RT for de-esterification. For measurements, cells (4x10⁶) were spun down in a microtube (1ml), resuspend in 1ml of F15 at 37°C, transferred to a quartz cuvette containing a fluorometric stir bar and 1ml of the same buffer at 37°C, and fluorescence signals were measured in the fluorometer.

*FRET.* Dynamic FRET imaging was carried out using a Nikon Eclipse TE2000-U microscope (Nikon, Melville, NY) equipped with a Dual-View (Optical Insights, Tucson, AZ) and CFP/YFP dual-band filter set (Chroma, Rockingham, VT). TIRF imaging was performed with a white light TIRF aperture diaphragm and a 100X TIRF 1.49 NA oil immersion objective coupled to a QuantEM EMCCD (Roper Scientific, Tucson, AZ). The microscope was controlled by NIS element software (Nikon, Melville, NY) and data analysis was performed with AutoDeblur (Autoquant Imaging, Troy, NY) by the sensitized emission method (Gordon et al., Biophys. J. 74:2702 (1998)). 48 hours after co-transfection with hEPCR-mCFP and βl-mYFP DNA
construct in Delta T dish (Fisher Scientific, Pittsburgh, PA), HEK293 cells were washed with PBS and then 1 ml L15 medium supplemented with 2 mg/ml D-glucose. Cells were equilibrated for about 10 minutes at 37°C in a FCS2 live cell imaging chamber (Bioptechs, Butler, PA). Then each image of CFP, YFP, and bright field of cells was taken for 0.1 second for hEPCR-mCFP and 1 second for βl-mYFP with 2 x 2 binning through a 100x oil immersion objective lens every 10 seconds for 15 minutes.

*Neutrophil recruitment into airspace.* Mice (C57BL/6, 6-8 weeks) were anesthetized with avertin and then intranasally administered 30 µg of LPS (Sigma-Aldrich, St. Louis, MO). Two hours later the mice were tail vein injected with rhAPC or RGE-APC (10 µg/mouse) or PBS. Mice were sacrificed 4 hours later and bronchoalveolar lavage was harvested. Cells were fixed with 4% formaldehyde for 20 minutes. Cells were counted using microbeads (Polyscience, Niles, IL) by flow cytometry. Cells were stained with Gr-I APC antibody (eBioscience, San Diego, CA) and collected by flow cytometry. Data were analyzed using FlowJo software (Tree Star, Ashland, OR).

*Induction of sepsis by cecal ligation and puncture (CLP).* CLP was used to induce acute septic peritonitis as described (Rhee et al., J Surg Res 115:74 (2003)). Briefly, mice (C57BL/6, 6-8 weeks) were anesthetized using inhaled Isofiurane, a midline incision (approximately 1 cm) was made below the diaphragm, the cecum was excised to the surface, ligated approximately 4 cm distal and then punctured through and through with a 22-gauge needle. Cecum was gently squeezed to excise its contents. Sham animals underwent the same procedure with no ligation or puncture. The abdominal incision was then closed in layers with Ethilon 6.0 suture. Mice were resuscitated with 1.0 ml of Ringer's solution via subcutaneous injection. Animals recovered under a heat lamp for approximately 30 minutes and were allowed food and water ad lib.

**Results**

After transendothelial migration, neutrophils cross the basal lamina and migrate through the extracellular matrix and into tissue or sites of inflammation. To investigate the effects of rhAPC on neutrophil adhesion to the matrix proteins, a cell adhesion assay was performed on fibronectin (FN)-coated cover glass. Human neutrophils were allowed to adhere to immobilized FN in the presence of the chemoattractant, N-formyl-Met-Leu-Phe (fMLP). The addition of rhAPC
significantly reduced fMLP-induced adhesion. To investigate the effects of rhAPC on the migration of neutrophils on matrix proteins, live-cell imaging of neutrophils migrating on fibronectin (FN)-coated cover glass was performed in the presence of fMLP. Cell tracking analysis revealed that fMLP significantly increased the random migration of neutrophils on FN, and the presence of rhAPC dramatically reduced this effect (Fig. IA).

During an infection, chemoattractants are released from various sources including the vascular endothelium, interstitial cells (macrophages and mast cells), and the infectious agent itself. Directional migration of neutrophils toward the chemokine gradients is critical to reach the site of infection. Therefore, the effect of rhAPC on neutrophil directional migration was tested using the under-agarose assay. Neutrophils were seeded in a well flanked by two wells containing either fMLP or PBS (Fig. IB, upper panel). The majority of neutrophils migrated toward the fMLP-containing well, suggesting that the chemoattractant diffused toward the middle well. As with random migration, rhAPC decreased directional migration of neutrophils on FN towards fMLP (Fig. IB). The effect of rhAPC on the dynamics of directional neutrophil migration was further investigated using the micropipette assay. In this assay, a micropipette tip containing fMLP was placed in a field of cells to establish a chemokine gradient. Consistent with results obtained using the under-agarose assay, neutrophil migration on FN toward the tip was dramatically decreased by rhAPC pretreatment (Fig. 1C). Quantitative analysis of over 30 neutrophils in each group revealed that rhAPC decreased the average lateral migration speed (S) more than 2.5 fold, without significantly altering the migratory index (distance from origin/total distance traveled; MI) or the direction of movement (KD) (Fig. 1C). These results indicate that, although neutrophils can sense chemoattractants and become polarized toward chemoattractant gradients in the presence of rhAPC, they cannot move toward the gradient. This was further supported by measurement of intracellular calcium mobilization by fMLP in the presence/absence of rhAPC. Dynamic measurement of intracellular Ca^{2+} showed that rhAPC had no effect on the increase in Ca^{2+} concentration by fMLP treatment (Fig. IE), suggesting that rhAPC did not functionally alter the signaling pathway associated with chemotaxis receptors on neutrophil.
Neutrophils must follow both endogenous and bacterial chemoattractant signals out of the vasculature and through the interstitium to arrive at a site of infection. To investigate whether rhAPC inhibited neutrophil migration induced by host-derived chemoattractants, IL-8 was used in the migration assay. Consistent with results obtained using fMLP, neutrophil migration on FN by IL-8 was dramatically decreased by rhAPC pre-treatment (Fig. 1D). In accord with its ability to block neutrophil migration, rhAPC also abolished the adhesion of human neutrophils to immobilized FN induced by fMLP (Fig. 2A).

The best characterized integrin binding motif is the RGD sequence, which is present in FN, fibrinogen, von Willebrand factor, vitronectin, and a variety of other adhesion proteins. Many integrins that bind to extracellular protein ligands including α3β1, α5β1, αIIbβ3, and αVβ3, specifically interact with the RGD sequence of their target proteins. As shown in Fig. 2B, amino acid sequence analysis revealed that the catalytic domain of human protein C and APC also contains the RGD sequence. Therefore, it was hypothesized that rhAPC directly interacts with neutrophil integrins to regulate cell migration. To test this hypothesis, rhAPC-binding assays were performed with neutrophils in suspension. The assay buffer containing ImM Ca^{2+} and ImM Mg^{2+} was supplemented with ImM Mn^{2+} to activate cell surface integrins. This significantly increased rhAPC binding to the neutrophil surface (Fig. 2C). The addition of blocking mAbs against β1 or β3 integrins partially displaced rhAPC from the cell surface (Fig. 2C). The presence of both β1 and β3 integrin blocking mAbs further reduced rhAPC binding on neutrophil surface (Fig. 2C). Cyclic RGD peptide also significantly inhibited rhAPC binding, while blocking anti-β2 integrin (non-RGD binding integrin) mAb had no effect (Fig. 2C). Collectively, these results showed that the major mechanism that controls rhAPC binding to the neutrophil surface was through direct interaction with the integrins.

Upon ligand binding, integrins undergo pronounced conformational changes that result in the appearance of ligand-induced binding sites (LIBS), which can be detected by specific monoclonal antibodies. The direct binding of rhAPC to β1 and β3 integrins on intact neutrophils was tested by measuring the appearance of LIBS using B44 mAb (β1 integrin LIBS Ab) and D3 mAb (β3 integrin LIBS Ab). In the presence of ImM Ca^{2+} and Mg^{2+}, rhAPC strongly induced B44 and D3 binding (Fig. 2D). The binding of APC to EPCR is Ca^{2+}-dependent, with ion concentrations of
3mM CaCl₂ and 0.6mM MgCb being optimal for binding (Liaw et al., J. Biol. Chem. 276:8364 (2001)). However, Ca²⁺ has been shown to exert a negative regulatory effect on integrin-ligand binding (Ruoslahti, Annu. Rev. Biochem. 57:375 (1988)). Consistent with this finding, APC did not induce the LIBS Abs binding in the presence of 3mM CaCl₂ and 0.6mM MgCl₂ (Fig. 2D). These data suggested that APC induced conformational changes in neutrophil integrins through direct interaction with the integrins and not through signals resulting from its interaction with EPCR on the neutrophil surface.

Among the neutrophil integrins that recognize the RGD motif, α3β1, α5β1, and αvβ3 are key in regulating neutrophil chemotaxis (Yauch et al., Mol. Biol. Cell 9:2751 (1998); Burns et al., J. Immunol. 166:4644 (2001); Sixt et al., J. Biol. Chem. 276:18878 (2001)). To test whether APC can bind directly to the integrins, an ELISA-like solid phase receptor-binding assay was performed (Fig. 2E). Soluble α3β1, α5β1, and αvβ3 were captured onto microtiter wells using mAbs specific for β1 or β3. Binding to FN or rhAPC was then measured in buffer containing ImM Mn²⁺, ImM Ca²⁺, and ImM Mg²⁺. As shown in Fig. 2E, FN and rhAPC bound to all three integrins, and this binding was specific, as shown by its reversibility in the presence of integrin-blocking mAbs.

To determine whether rhAPC binds to β1 and β3 integrins through its RGD sequence, the RGD sequence was mutated to RGE (RGE-APC). SDS-PAGE analysis of protein C zymogens prior to and following activation by thrombin indicated that the molecular weight and glycosylation of RGE-APC was similar to that of wild type APC. Enzyme assays using the chromogenic substrate, S-2366, revealed that the Km and kcat of RGE-APC were also comparable to those for wild-type APC (Table 2).

<table>
<thead>
<tr>
<th>Table 2. Enzyme kinetic constants of wild type APC and RGE-APC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Kₘ</td>
</tr>
<tr>
<td>kₖcat</td>
</tr>
<tr>
<td>kₖcat/Kₘ</td>
</tr>
</tbody>
</table>

Despite these similarities, the direct binding of RGE-APC to soluble α3β1, α5β1, and αvβ3 integrins was significantly less than that of wild type APC, as measured by the
solid phase receptor-binding assays (Fig. 2F). In random migration assay, RGE-APC had no effect on the migration of neutrophils on FN, while the presence of wild type rhAPC dramatically reduced the migration (Fig. 2G). To investigate whether activation of PC is required for the inhibition of neutrophil migration and adhesion, the zymogen PC (rhPC) was tested in migration and adhesion assays. Unlike rhAPC, rhPC failed to block neutrophil migration on FN (Fig. 2G) and also failed to block neutrophil adhesion. The recombinant APC variant S360A-APC, however, which lacks proteolytic activity (Gale et al., Protein Sci. 6:132-140 (1997)) successfully inhibited neutrophil migration. Thus, these data show that the RGD sequence in rhAPC was an essential feature of its direct interaction with the neutrophil integrins and for inhibition of neutrophil migration on matrix proteins. These data also show that APCs enzymatic proteolytic activity is not necessary for the inhibition.

EPCR was the first identified cellular APC receptor and is expressed in healthy human neutrophils and monocytes (Sturn et al., Blood 102:1499 (2003)). Because activated neutrophils contribute to organ system dysfunction and mortality in sepsis, we first compared EPCR expression between unstimulated and fMLP-stimulated neutrophils. Reverse-transcription PCR revealed that healthy neutrophils expressed EPCR mRNA (Fig. 3A). Cell surface expression of EPCR could also be detected in these cells, although the overall levels of the receptor were very low (Fig. 3A). Stimulation with fMLP dramatically enhanced cell surface expression of EPCR (Fig. 3A).

Previously, it was shown that neutrophil migration through nitrocellulose micropore filter (without any protein coatings) was inhibited by rhAPC and the inhibition was reversed by an EPCR blocking Ab (Sturn et al., Blood 102:1499 (2003)). However, in our neutrophil adhesion assay to immobilized FN, Glα-less APC, a mutant form of APC that lacks the EPCR binding motif (Regan et al., J. Biol. Chem. 272:26279 (1997)), inhibited adhesion to a slightly less, but similar, degree as the wild type protein (Fig. 2A). Therefore, it was tested whether the anti-EPCR antibody relieved the rhAPC-induced inhibition of neutrophil adhesion on FN.

Blocking of neutrophil EPCR with high concentration of antibody only partially, but significantly, reversed the inhibitory effect of rhAPC on neutrophil binding to FN (Fig. 3B). In endothelial cells, EPCR-bound APC can mediate signals through PAR-I (Riewald et al., Science 296:1880 (2002)) and SIPI receptors (Feistritzer and
Riewald, Blood 105:3178 (2005); Finigan et al, J. Biol. Chem. 280:17286 (2005)). However, agonists of PAR-I (SFLLRNPNNDKYEPEF (SEQ ID NO:39)) and SIP1 (SEW2871) did not reverse the inhibitory effect of rhAPC on neutrophil migration. Thus these results show that rhAPC can bind to EPCR and β1/β3 integrins simultaneously on the neutrophil surface (Fig. 3C), where EPCR provides a supportive role for the integrin binding. To investigate the double occupation of rhAPC on living cell surface, fluorescence resonance energy transfer (FRET) analysis was employed to measure the energy transfer between monomeric yellow fluorescent protein (mYFP) and monomeric cyan fluorescent protein (mCFP) as a function of distance (Fig. 3C). A C-terminal CFP-tagged EPCR (EPCR-mCFP) and YFP-tagged β1 integrin (β1-mYFP) were constructed (Fig. 3C and 3D). EPCR-mCFP and β1-mYFP were transiently co-transfected into the EPCR deficient HEK293, where they localized predominantly to the plasma membrane (Fig. 3E). To test if there was a decrease in the distance between EPCR and β1 integrins by rhAPC ligation, dynamic FRET was used to measure changes in the relative proximity of these cell surface proteins in the presence of rhAPC or GLA-less APC. Since the ligand will only bind to cell surface receptors, optical measurements were confined to the plasma membrane using through the objective total internal reflection fluorescence (TIRF). Dynamic FRET measurements on TIRF microscopy showed a significant increase in FRET efficiency after rhAPC treatment (Fig. 3F). No obvious FRET change was observed with Gla-less APC (Fig. 3F). Therefore these data support the hypothesis that rhAPC recruits EPCR and β1 integrins in close proximity, within 100 A, on cell membrane through simultaneous binding to EPCR and the integrins. Intravenous administration of rhAPC is known to reduce lipopolysaccharide (LPS)-induced pulmonary inflammation by attenuating neutrophil chemotaxis towards the alveolar compartment. To show that the protective effect of rhAPC \textit{in vivo} is associated with its interaction with neutrophil integrins and its suppression of neutrophil migration, LPS instillation induced neutrophil recruitment into bronchoalveolar lavage fluid (BALF) was determined by flow cytometry. Neutrophil recruitment in the BALF was significantly reduced by rhAPC, but not by RGE-APC, injection (Fig. 4A). To further prove that the RGD sequence in rhAPC is important for its beneficial effects in sepsis, cecal ligation and puncture (CLP) was induced and the survivals of septic mice were measured in the absence or presence of a RGD
peptide that has high affinity to both β1 and β3 integrins (acetyl-c[(penicillamine)-(9-methyltyronsine-ARGDN(tetrahydroisoquinoline-3-carboxylic acid)]C-NH₂; Mattern et al, Cancer Ther. 3A:325 (2005)). In 'mid-grade' sepsis (50% survival) (Rittirsch et al., Nat. Med. 14:551 (2008)), treatment of mice with the RGD peptide reproducibly prolonged the time of survival, but there was no significant change in the 7-day mortality (Fig. 4B). Administration of rhAPC significantly reduced mortality in a subset of patients with severe sepsis (Bernard et al., N. Engl. J. Med. 344:699 (2001)), and currently it is indicated for use in patients with sepsis involving acute organ dysfunction and a high risk of death. In order to examine whether the RGD peptide alters mortality in 'high-grade' sepsis, 90% mortality was induced by endotoxemia. When LPS was given at LD₉₀, a single dose of the RGD peptide reduced mortality from 90 to 60% (Fig. 4C). These findings demonstrated that the blocking of integrins by rhAPC was critical for the inhibition of neutrophil recruitment and for the protection in sepsis.

Given the complexity of the systemic inflammatory response to infection, it is not surprising that many targeted therapies in sepsis have not been able to improve survival. rhAPC was the first drug approved by the FDA for this indication but its broad application has been questioned. Nonetheless, improvements in current APC therapy and development of better targeted, more efficient anti-sepsis therapies have been hampered by a lack of understanding of the exact mechanisms underlying the beneficial effects of rhAPC on organ function and survival rate in sepsis. The results presented here demonstrate that rhAPC inhibits neutrophil adhesion and migration on extracellular matrix proteins by directly binding to integrins (β1 and β3 integrins) at the neutrophil surface. Therefore, leukocyte integrins are cellular receptors for rhAPC and specific APC-integrin interactions inhibit neutrophil migration. If the beneficial effects of rhAPC on sepsis are mediated, in part, by diminishing integrin-mediated neutrophil infiltration into the inflamed tissue, then anti-integrin reagents may be used as therapies for severe sepsis or as a combination therapy with rhAPC to improve the clinical outcomes of rhAPC treatment.

**Example 2. rhAPC Mutants with High Affinity for Integrins.**

If the primary effects of rhAPC on sepsis are attributable both to protection of endothelium and to changes in integrin-mediated neutrophil migration, then modifications of rhAPC that have higher affinity to the neutrophil integrins, and still
affect endothelial function through the EPCR, may result in a more potent and better-targeted anti-sepsis therapy.

The crystal structures of the complex of RGD peptide and integrin αVβ3 have been solved. The peptide binds with its Arg contacting the α subunit/β propeller domain and its Asp ligated to a Mn²⁺ held in the metal ion-dependent adhesion site (MIDAS) of the β subunit I-like domain. The calculated buried area of the RGD motif in the αVβ3 crystal is 373A, which is close to the reported value, 355A. The solvent accessible surface area of rhAPC RGD motif was calculated, which is comparable to the buried area of the complex. The solvent accessible surface area of rhAPC RGD motif was 140A. A main reason for the small buried area was that the light chain covers a part of the RGD motif in the catalytic domain (Fig. 5).

Specifically, the C-terminal of the light chain covered the RGD motif of the catalytic domain. The light chain was removed and the buried area of the rhAPC RGD motif was recalculated. The buried area of the RGD motif was 208A. However, the area of the RGD motif was still smaller than that of αVβ3 (Table 3).

Table 3. RGD Motif Surface Accessible Areas.

<table>
<thead>
<tr>
<th></th>
<th>Buried Area</th>
<th>Sum</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>R</td>
<td>G</td>
</tr>
<tr>
<td>αVβ3 + RGD (1L5G.pdb)</td>
<td>163.07</td>
<td>66.2</td>
</tr>
<tr>
<td>APC (1AUT.pdb): with light chain</td>
<td>88.92</td>
<td>13/19</td>
</tr>
<tr>
<td>APC (1AUT.pdb): without light chain</td>
<td>91.42</td>
<td>39.03</td>
</tr>
</tbody>
</table>

These data show that accessibility of the RGD motif in wild type rhAPC was not optimal for integrin binding.

The structures of rhAPC RGD motif and RGD peptide in complex were compared with αVβ3. The coordinates were superimposed and it was found that the two structures are different. The rhAPC RGD motif had a different side-chain orientation compared to the αVβ3 RGD motif, which suggested the presence of potential steric clash when the wild type rhAPC RGD motif binds to the integrins.
To increase the affinity of APC for integrins, the accessibility and structure of the RGD motif was altered. As mentioned above, the conformation of the RGD motif was not optimal for integrin binding. Therefore, subtle conformational changes around the area were used to enhance the affinity of APC to the integrins.

A broad-range of hosts and scaffolds based on ribosome display, phage display, and cell-surface display are used widely as systems to implement directed evolution (Hoogenboom, Nat. Biotechnol. 23:1105 (2005)). Among the cell surface display systems based on microbial and eukaryotic hosts, the yeast system offers the unique advantage of eukaryotic machinery that enables post-translational modification, glycosylation, and disulfide isomerization (Wittrup, Curr. Opin. Biotechnol. 12:392 (2001)). The yeast surface display was used to screen variants of high affinity rhAPC. The yeast display system that was used employs the α-agglutinin yeast adhesion receptor to display recombinant proteins on cell surface of *S. cerevisiae*. The receptor consists of two proteins, Agal and Aga2 (Fig. 6). Agal is secreted and becomes covalently attached to β-glucan in the extracellular matrix of the yeast cell wall. Aga2 binds to Agal through two disulfide bonds, making it possible to express a protein of interest fused to Aga2.

A cDNA library was constructed by error-prone PCR using nucleotide analogues and a mutagenesis kit (GeneMorph® II Random Mutagenesis Kit, Stratagene, La Jolla, CA) to introduce a comparable ratio of transition (purine to purine or pyrimidine to pyrimidine) to transversion (purine to pyrimidine or pyrimidine to purine) mutations. Mixtures of 1 μg cDNA library and 0.5 μg of the NheI/BamHI linearized pCTCON vector in 5 μl were transformed into $10^8$ yeast cells by electroporation, which lead to ~10⁶ diversity in the library. Inside the cells, the cDNA library was recombined into the vector by the endogenous Gap repair protein. The yeast library of the human protein C was activated by thrombin. Progressive enrichment of cells encoding high affinity APC was done by panning. Yeast cells that display APC variants were allowed to bind to β1 and β3 integrin expressing HEK293T cells. Yeast cells with high affinity APC remained bound, while others were removed by washing. Those that remained were eluted for further analysis.

The mutant APC yeast library was selected by panning on HEK293T cells. After five cycles of panning (Figs. 7A and 7B), the percentage of cells that bound to HEK293T cells was dramatically increased. A total of 20 yeast colonies selected with
panning were sequenced. Of these, 12 had unique sequences and were designated as C212R (the amino acid sequence was numbered as described (Mather et al., EMBO J. 15:6822 (1996))) (Fig. 8). This mutation is distantly located from the RGD motif. However, the disulfide bond formed by C212 connects anti-parallel beta-sheets, which are directly connected to the loops including RGD motif. Therefore, the mutation could destabilize the structure and expose the RGD motif for more favorable integrin binding.

A second panning of the mutant APC yeast library on HEK293T cells was performed. After five cycles of panning, the percentage of cells bound to HEK293T cells was dramatically increased. More than 50 yeast colonies selected with the second round of panning were sequenced. Of these, 12 had the unique sequence designated as D172N (SEQ ID NO:43). This mutation is distantly located from the RGD motif.

A rational design approach to generate high affinity mutant APC was also employed. According to the crystal structure of human APC, several neighboring positive charged amino acids form hydrogen bonds with the RGD sequence. Mutations to remove the hydrogen bonds were constructed and displayed on the yeast surface. Mutant APCs, KR146/147GG-APC and R177G-APC, showed enhanced binding compared to WT APC (Fig. 9A). When these mutations were combined (KR146/147GG+R177G), the adhesion was further enhanced (Figs. 9A and 9B). An additional mutation, K146R, was also identified. The data suggest that these point mutations increased the affinity of APC to integrins.
WHAT IS CLAIMED IS:

1. A nucleic acid sequence encoding an activated protein C comprising one or more amino acid substitutions selected from the group consisting of K146R, D172N, C212R, K146G, R147G, and R177G.

2. The nucleic acid sequence of claim 1, wherein the activated protein C comprises the amino acid substitutions K146G and R147G.

3. The nucleic acid sequence of claim 1, wherein the activated protein C comprises the amino acid substitutions R177G, K146G and R147G.

4. The nucleic acid sequence of claim 1, wherein the activated protein C comprises the amino acid substitutions C212R, K146G and R147G.

5. The nucleic acid sequence of claim 1, wherein the activated protein C comprises the amino acid substitutions C212R and R177G.

6. The nucleic acid sequence of claim 1, wherein the activated protein C comprises the amino acid substitution K146R or D172N.

7. The nucleic acid sequence of claim 1, wherein the nucleic acid sequence comprises SEQ ID NO:1.

8. The nucleic acid sequence of any one of claims 1-7, wherein the encoded activated protein C comprises an RGD motif.

9. The nucleic acid of any one of claims 1-7, wherein the activated protein C further comprises the amino acid substitutions RR229/230AA.

10. The nucleic acid of any one of claims 1-7, wherein the activated protein C further comprises the amino acid substitutions KKK191-193AAA.

11. The nucleic acid of any one of claims 1-7, wherein the activated protein C further comprises the amino acid substitutions BCKK191-193AAA and RR229/230AA.

12. A nucleic acid sequence encoding an activated protein C comprising the amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:42 and SEQ ID NO:43.
13. A nucleic acid sequence comprising a substitution-encoding fragment of any one of the nucleic acid sequences of claim 12.

14. A composition comprising the nucleic acid of 12 or 13 and a pharmaceutically acceptable excipient.

15. A kit comprising the nucleic acid of claim 12 or 13 and a container.

16. A cell comprising the nucleic acid of claim 12 or 13.

17. A polypeptide comprising an activated protein C comprising one or more amino acid substitutions selected from the group consisting of K146R, D172N, C212R, K146G, R147G, and R177G.

18. The polypeptide of claim 17, wherein the activated protein C comprises the amino acid substitutions K146G and R147G.

19. The polypeptide of claim 17, wherein the activated protein C comprises the amino acid substitutions R177G, K146G and R147G.

20. The polypeptide of claim 17, wherein the activated protein C comprises the amino acid substitutions C212R, K146G and R147G.

21. The polypeptide of claim 17, wherein the activated protein C comprises the amino acid substitutions C212R and R177G.

22. The polypeptide of claim 17, wherein the activated protein C comprises the amino acid substitution K146R or D172N.

23. The polypeptide of claim 17, wherein the polypeptide comprises SEQ ID NO:1.

24. The polypeptide of any one of claims 17-23, wherein the encoded activated protein C comprises an RGD motif.

25. The polypeptide of any one of claims 17-23, wherein the activated protein C further comprises the amino acid substitutions RR229/230AA.

26. The polypeptide of any one of claims 17-23, wherein the activated protein C further comprises the amino acid substitutions KKK191-193AAA.

27. The polypeptide of any one of claims 17-23, wherein the activated protein C further comprises the amino acid substitutions KKK191-193AAA and RR229/230AA.

28. A polypeptide comprising an activated protein C comprising an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ
ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:42 and SEQ ID NO:43.

29. A polypeptide comprising a fragment of the polypeptide of claim 28, wherein the fragment includes one or more of the amino acid substitutions selected from the group consisting of K146R, D172N, C212R, K146G, R147G, and R177G.

30. A composition comprising the polypeptide of claim 28 or 29 and a pharmaceutically acceptable excipient.

31. A kit comprising the polypeptide of claim 28 or 29 and a container.

32. A cell comprising the polypeptide of claim 28 or 29.

33. A method of treating sepsis in a subject comprising administering to the subject the nucleic acid of any one of claims 1-7 or 12.

34. The method of claim 33, wherein the nucleic acid is administered by a vector comprising the nucleic acid.

35. The method of claim 34, wherein the vector is a bacterial or viral vector.

36. A method of treating sepsis in a subject comprising administering to the subject the composition of claim 14.

37. A method of treating sepsis in a subject comprising administering to the subject the polypeptide of claim 28 or 29.

38. A method of treating sepsis in a subject comprising administering to the subject the composition of claim 30.

39. A method of treating sepsis in a subject comprising administering to the subject a variant activated protein C comprising one or more amino acid substitutions selected from the group consisting of K146R, D172N, C212R, K146G, R147G, and R177G.

40. The method of claim 39, wherein the variant activated protein C comprises the amino acid substitutions K146G and R147G.

41. The method of claim 39, wherein the variant activated protein C comprises the amino acid substitutions R177G, K146G and R147G.

42. The method of claim 39, wherein the variant activated protein C comprises the amino acid substitutions C212R, K146G and R147G.
43. The method of claim 39, wherein the variant activated protein C comprises the amino acid substitutions C212R and R177G.

44. The method of claim 39, wherein the variant activated protein C comprises the amino acid substitution K146R or D172N.

45. The method of any one of claims 39-44, wherein the variant activated protein C comprises an RGD motif.

46. The method of any one of claims 39-44, wherein the variant activated protein C further comprises the amino acid substitutions RR229/230AA.

47. The method of any one of claims 39-44, wherein the variant activated protein C further comprises the amino acid substitutions KKK191-193AAA.

48. The method of any one of claims 39-44, wherein the variant activated protein C further comprises the amino acid substitutions KKK191-193AAA and RR229/230AA.

49. The method of claim 39, wherein the variant activated protein C comprises an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:42 and SEQ ID NO:43.

50. The method of any one of claims 33-36, 38-44 or 49, further comprising administering a therapeutic agent to the subject.

51. The method of claim 50, wherein the therapeutic agent is selected from the group consisting of antibiotics, anti-inflammatory agents, vasopressors, pain killers, and sedatives.

52. The method of claim 51, wherein the anti-inflammatory agent is a corticosteroid.

53. The method of claim 50, wherein the therapeutic agent is an antibody that blocks β1 or β3 integrin activity.

54. A method of screening for polypeptides with enhanced activated protein C activity comprising
(a) contacting a polypeptide to be tested with a cell expressing one or both of β1 integrin and β3 integrin, wherein the polypeptide to be tested comprises activated protein C or a fragment thereof comprising one or more amino acid substitutions; and
(b) determining whether the polypeptide to be tested binds to the β1 integrin or β3 integrin better than a control activated protein C or fragment thereof, wherein binding better than the control indicates the polypeptide to be tested has enhanced activated protein C activity.

55. The method of claim 54, wherein the contacting step includes contacting a cell expressing the polypeptide to be tested with the cell expressing one or both of β1 integrin and β3 integrin.

56. The method of claim 54, wherein the polypeptide to be tested is made by mutagenizing activated protein C or a fragment thereof using error-prone PCR.

57. The method of any one of claims 54-56, wherein the control activated protein C comprises SEQ ID NO:1.

58. A method of screening for an agent for treatment of sepsis comprising
(a) contacting the agent to be screened with a cell expressing one or both of β1 integrin and β3 integrin;
(b) contacting an activated protein C or fragment thereof with the cell; and
(c) determining whether the agent competes with APC for binding to the β1 integrin or β3 integrin, wherein the agent competing with APC for binding indicating the agent is suitable for treatment of sepsis.

59. The method of claim 58, wherein the activated protein C comprising SEQ ID NO:1.

60. The method of claim 58 or 59, wherein the activated protein C or fragment thereof comprises an RGD motif.

61. A method of treating sepsis in a subject comprising administering to the subject a pharmaceutical composition comprising one or more RGD-containing peptides.

62. The method of claim 61, wherein the RGD-containing peptide is a cyclic RGD-containing peptide.

63. The method of claim 61 or 62, wherein the RGD-containing peptide is selected from the group consisting of c[RGDD(tet-butylglycine)(w-aminomethylbenzoic acid)]; c[(3-mercaptopropionic acid)RGDD(te/t-butylglycine)C]-NH₂; G-
c[(pencillamine)RARGDNPC]-A; acetyl-c[(penicillamine)-O-methyltyrosine-ARGDN(tetrahydroisoquinoline-3-carboxylic acid)C]-NH\textsubscript{2}, and acetylphenylalanine-c[CRGDTFC]-NH\textsubscript{2}.

64. The method of claim 61, wherein the RGD-containing peptide is acetyl-c[(penicillamine)-(9-methyltyrosine-ARGDN(tetrahydroisoquinoline-3-carboxylic acid)C]-NH\textsubscript{2}.

65. The method of claim 61, further comprising administering a therapeutic agent to the subject.

66. The method of claim 65, wherein the therapeutic agent is selected from the group consisting of antibiotics, anti-inflammatory agents, vasopressors, pain killers, and sedatives.

67. The method of claim 66, wherein the anti-inflammatory agent is a corticosteroid.

68. The method of claim 61, wherein the therapeutic agent is an antibody that blocks β1 or β3 integrin activity.

69. The method of claim 61, further comprising administering the composition of claim 14 or 30 to the subject.

70. The method of claim 61, further comprising administering an activated protein C or fragment thereof to the subject.

71. The method of claim 70, wherein the activated protein C comprises SEQ ID NO:1.
FIG. 1A

FIG. 1B
FIG. 1E

FIG. 2A
Human FN: YAVTG RGDSPAS

Human PC: GKMTR RGDSPWQ

FIG. 2B

![Graph showing bound APC (OD 405nm)](image)

FIG. 2C
<table>
<thead>
<tr>
<th>mAbs</th>
<th>Cation</th>
<th>Treatment</th>
<th>LIBS induction (% Control)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1mM Mg$^{2+}$+1mM Ca$^{2+}$</td>
<td>PBS</td>
<td><img src="image1" alt="Graph" /></td>
</tr>
<tr>
<td></td>
<td>1mM Mg$^{2+}$+1mM Ca$^{2+}$</td>
<td>APC</td>
<td><img src="image2" alt="Graph" /></td>
</tr>
<tr>
<td></td>
<td>0.6mM Mg$^{2+}$+3mM Ca$^{2+}$</td>
<td>PBS</td>
<td><img src="image3" alt="Graph" /></td>
</tr>
<tr>
<td></td>
<td>0.6mM Mg$^{2+}$+3mM Ca$^{2+}$</td>
<td>APC</td>
<td><img src="image4" alt="Graph" /></td>
</tr>
</tbody>
</table>

**FIG. 2D**

![Graph](image5)

**FIG. 2E**

![Graph](image6)
FIG. 2F
FIG. 3A
FIG. 3B
FIG. 3C

FIG. 3D
FIG. 3E

FIG. 3F
Integrin

APC

cMyc

Aga2

S

Aga1

Cell wall

Yeast

Plasma membrane

FIG. 6

FIG. 7A
FIG. 7B